SCHEMBL3709728

SCHEMBL3709728

Cc1[c]cc(NC(=O)c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.64
HTT P42858 1/20 0.64
RAB9A P51151 1/20 0.64
KMT2A Q03164 1/20 0.64
KCNK3 O14649 2/20 0.63
KCNK9 Q9NPC2 1/20 0.63
P2RX1 P51575 1/20 0.63
LMNA P02545 1/20 0.63
PTGS1 P23219 2/20 0.62
MAPT P10636 1/20 0.60
GAA P10253 1/20 0.57
KCNQ3 O43525 2/20 0.56
KCNQ2 O43526 2/20 0.56
KCNE1 P15382 2/20 0.56
KCNQ1 P51787 2/20 0.56
BRAF P15056 3/20 0.56
ALDH1A1 P00352 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
KCNQ5 Q9NR82 1/20 0.55
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8363755 0.82 MEN1 (0.77) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL28668959 0.81 LMNA (0.83) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL12858422 0.80 MEN1 (0.73) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL4909972 0.79 LMNA (0.70) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL4286068 0.79 MAPT (0.94) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL12764063 0.79 MEN1 (1.00) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL30739967 0.78 LMNA (0.78) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL24249928 0.78 MEN1 (0.70) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL1264161 0.78 MEN1 (0.70) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL2858703 0.78 MAPT (0.70) MEN1HTTRAB9AKMT2AKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US claimed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP claimed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO claimed
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR MEN1 2034/4885HTT 1173/4885RAB9A 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.